1
|
Buthelezi LA, Pillay S, Ntuli NN, Gcanga L, Guler R. Antisense Therapy for Infectious Diseases. Cells 2023; 12:2119. [PMID: 37626929 PMCID: PMC10453568 DOI: 10.3390/cells12162119] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Revised: 08/15/2023] [Accepted: 08/17/2023] [Indexed: 08/27/2023] Open
Abstract
Infectious diseases, particularly Tuberculosis (TB) caused by Mycobacterium tuberculosis, pose a significant global health challenge, with 1.6 million reported deaths in 2021, making it the most fatal disease caused by a single infectious agent. The rise of drug-resistant infectious diseases adds to the urgency of finding effective and safe intervention therapies. Antisense therapy uses antisense oligonucleotides (ASOs) that are short, chemically modified, single-stranded deoxyribonucleotide molecules complementary to their mRNA target. Due to their designed target specificity and inhibition of a disease-causing gene at the mRNA level, antisense therapy has gained interest as a potential therapeutic approach. This type of therapy is currently utilized in numerous diseases, such as cancer and genetic disorders. Currently, there are limited but steadily increasing studies available that report on the use of ASOs as treatment for infectious diseases. This review explores the sustainability of FDA-approved and preclinically tested ASOs as a treatment for infectious diseases and the adaptability of ASOs for chemical modifications resulting in reduced side effects with improved drug delivery; thus, highlighting the potential therapeutic uses of ASOs for treating infectious diseases.
Collapse
Affiliation(s)
- Lwanda Abonga Buthelezi
- International Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town 7925, South Africa; (L.A.B.); (S.P.); (N.N.N.); (L.G.)
- Department of Pathology, Division of Immunology, Institute of Infectious Diseases and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa
| | - Shandre Pillay
- International Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town 7925, South Africa; (L.A.B.); (S.P.); (N.N.N.); (L.G.)
- Department of Pathology, Division of Immunology, Institute of Infectious Diseases and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa
| | - Noxolo Nokukhanya Ntuli
- International Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town 7925, South Africa; (L.A.B.); (S.P.); (N.N.N.); (L.G.)
- Department of Pathology, Division of Immunology, Institute of Infectious Diseases and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa
| | - Lorna Gcanga
- International Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town 7925, South Africa; (L.A.B.); (S.P.); (N.N.N.); (L.G.)
- Department of Pathology, Division of Immunology, Institute of Infectious Diseases and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa
| | - Reto Guler
- International Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town 7925, South Africa; (L.A.B.); (S.P.); (N.N.N.); (L.G.)
- Department of Pathology, Division of Immunology, Institute of Infectious Diseases and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa
- Faculty of Health Sciences, Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, Cape Town 7925, South Africa
| |
Collapse
|
2
|
Antisense Oligonucleotide-Based Therapy of Viral Infections. Pharmaceutics 2021; 13:pharmaceutics13122015. [PMID: 34959297 PMCID: PMC8707165 DOI: 10.3390/pharmaceutics13122015] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Revised: 11/23/2021] [Accepted: 11/23/2021] [Indexed: 02/07/2023] Open
Abstract
Nucleic acid-based therapeutics have demonstrated their efficacy in the treatment of various diseases and vaccine development. Antisense oligonucleotide (ASO) technology exploits a single-strand short oligonucleotide to either cause target RNA degradation or sterically block the binding of cellular factors or machineries to the target RNA. Chemical modification or bioconjugation of ASOs can enhance both its pharmacokinetic and pharmacodynamic performance, and it enables customization for a specific clinical purpose. ASO-based therapies have been used for treatment of genetic disorders, cancer and viral infections. In particular, ASOs can be rapidly developed for newly emerging virus and their reemerging variants. This review discusses ASO modifications and delivery options as well as the design of antiviral ASOs. A better understanding of the viral life cycle and virus-host interactions as well as advances in oligonucleotide technology will benefit the development of ASO-based antiviral therapies.
Collapse
|
3
|
Levina A, Repkova M, Shikina N, Ismagilov Z, Kupryushkin M, Pavlova A, Mazurkova N, Pyshnyi D, Zarytova V. Pronounced therapeutic potential of oligonucleotides fixed on inorganic nanoparticles against highly pathogenic H5N1 influenza A virus in vivo. Eur J Pharm Biopharm 2021; 162:92-98. [PMID: 33753212 DOI: 10.1016/j.ejpb.2021.03.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2020] [Revised: 12/20/2020] [Accepted: 03/14/2021] [Indexed: 11/26/2022]
Abstract
This study describes the effective attack of oligonucleotides on the viral genome of highly pathogenic H5N1 influenza A virus (IAV) in vivo using for the first time the new delivery system consisting of biocompatible low-toxic titanium dioxide nanoparticles and immobilized polylysine-containing oligonucleotides with the native (ODN) and partially modified (ODNm) internucleotide bonds. Intraperitoneal injection of the TiO2•PL-ODN nanocomposite provided 65-70% survival of mice, while intraperitoneal or oral administration of TiO2•PL-ODNm was somewhat more efficient (~80% survival). The virus titer in the lung was reduced by two-three orders of magnitude. The nanocomposites are nontoxic to mice under the used conditions. TiO2 nanoparticles, unbound ODN, and the nanocomposite bearing the random oligonucleotide showed an insignificant protective effect, which indicates the ability of targeted oligonucleotides delivered in mice in the nanocomposites to site-specifically interact with complementary RNAs. The protection of oligonucleotides in nanocomposites by TiO2 nanoparticles and partial modification of the internucleotide bonds provides a continued presence of oligonucleotides in the body for the effective and specific action on the viral RNA. The proposed oligonucleotide delivery system can claim not only to effectively inhibit IAV genes but also to turn off other genes responsible for diseases caused by nucleic acids.
Collapse
Affiliation(s)
- Asya Levina
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of RAS, pr. Lavrent'eva 8, 630090 Novosibirsk, Russia
| | - Marina Repkova
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of RAS, pr. Lavrent'eva 8, 630090 Novosibirsk, Russia
| | - Nadezhda Shikina
- Boreskov Institute of Catalysis, Siberian Branch of RAS, pr. Lavrent'eva 5, 630090 Novosibirsk, Russia
| | - Zinfer Ismagilov
- Boreskov Institute of Catalysis, Siberian Branch of RAS, pr. Lavrent'eva 5, 630090 Novosibirsk, Russia
| | - Maxim Kupryushkin
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of RAS, pr. Lavrent'eva 8, 630090 Novosibirsk, Russia
| | - Anna Pavlova
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of RAS, pr. Lavrent'eva 8, 630090 Novosibirsk, Russia
| | - Natalia Mazurkova
- FBRI State Research Centre of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk Region, Russia
| | - Dmitrii Pyshnyi
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of RAS, pr. Lavrent'eva 8, 630090 Novosibirsk, Russia
| | - Valentina Zarytova
- Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of RAS, pr. Lavrent'eva 8, 630090 Novosibirsk, Russia.
| |
Collapse
|
4
|
Yang L, Wang S, Wang Y, Zhao P, Cui C, Tu L, Li X, Yu Y, Li H, Wang L. Diversity of locally produced IFN-α subtypes in human nasopharyngeal epithelial cells and mouse lung tissues during influenza virus infection. Appl Microbiol Biotechnol 2020; 104:6351-6361. [PMID: 32472176 DOI: 10.1007/s00253-020-10676-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Revised: 04/30/2020] [Accepted: 05/10/2020] [Indexed: 11/24/2022]
Abstract
The excessively expressed interferon-α (IFN-α) might contribute to the uncontrolled inflammatory responses, causing pathological damage during influenza virus infection. However, the correlation of the pathological damage with the expression profile of IFN-α subtypes in the focus of infection with influenza viruses is poorly understood. To investigate this, we detected the IFN-α subtype dominance in human respiratory epithelial cells and mouse lungs, both of which were infected with influenza viruses. It was found that IFN-α1, IFN-α6, IFN-α14, and IFN-α16 were dominantly expressed in respiratory epithelial cells from the patients infected with IAV, whereas IFN-α5, IFN-α8, and IFN-α21 were dominantly expressed in respiratory epithelial cells from the patients infected with less pathogenic IBV and that IFN-α1, IFN-α9, and IFN-α15 were dominantly expressed in lungs of the mice infected with H1N1 IAV, and IFN-α2, IFN-α12, and IFN-α13 were dominantly expressed in lungs of the mice infected with less pathogenic H9N2 IAV. Compared with H9N2 IAV, H1N1 IAV induced higher mortality rates and more obvious body weight loss in the mice. In addition, IAV or H1N1 IAV induced a significantly higher level of CXCL10 mRNA in the human respiratory epithelial cells or the mouse lungs, respectively. In mice, the high level of Cxcl10 mRNA was accompanied by the abundant infiltrated neutrophils and more severe pathological changes in the lungs. Together, the data presented here indicate that the pathogenicity of influenza viruses is correlated with the IFN-α subtypes induced by influenza viruses. KEY POINTS: • Different influenza viruses induce differential inflammation responses. • Various influenza viruses induce diverse expression profiles of IFN-α subtypes. • The locally produced IFN-α subtypes correlated to the differential inflammation. Graphical abstract.
Collapse
Affiliation(s)
- Lei Yang
- Institute of Pediatrics in The First Hospital of Jilin University and Department of Molecular Biology in College of Basic Medical Sciences, Jilin University, Changchun, 130021, Jilin, People's Republic of China
| | - Shengnan Wang
- Institute of Pediatrics in The First Hospital of Jilin University and Department of Molecular Biology in College of Basic Medical Sciences, Jilin University, Changchun, 130021, Jilin, People's Republic of China
| | - Ying Wang
- Institute of Pediatrics in The First Hospital of Jilin University and Department of Molecular Biology in College of Basic Medical Sciences, Jilin University, Changchun, 130021, Jilin, People's Republic of China
| | - Peiyan Zhao
- Institute of Pediatrics in The First Hospital of Jilin University and Department of Molecular Biology in College of Basic Medical Sciences, Jilin University, Changchun, 130021, Jilin, People's Republic of China
| | - Cuiyun Cui
- Department of Immunology, College of Basic Medical Sciences, Jilin University, Changchun, 130021, Jilin, People's Republic of China
| | - Liqun Tu
- Department of Immunology, College of Basic Medical Sciences, Jilin University, Changchun, 130021, Jilin, People's Republic of China
| | - Xin Li
- Institute of Pediatrics in The First Hospital of Jilin University and Department of Molecular Biology in College of Basic Medical Sciences, Jilin University, Changchun, 130021, Jilin, People's Republic of China
| | - Yongli Yu
- Department of Immunology, College of Basic Medical Sciences, Jilin University, Changchun, 130021, Jilin, People's Republic of China
| | - Haibo Li
- Department of Pediatric Clinic, The First Hospital of Jilin University, Jilin University, Changchun, 130021, Jilin, People's Republic of China.
| | - Liying Wang
- Institute of Pediatrics in The First Hospital of Jilin University and Department of Molecular Biology in College of Basic Medical Sciences, Jilin University, Changchun, 130021, Jilin, People's Republic of China.
| |
Collapse
|
5
|
Ma Y, Zhao X, Jia J, Yang Y, Fan R, Lv M, Ding F, Wu J, Zhang J. Analysis of Protein Expression in Human Cells Cocultured with Porcine Peripheral Blood Mononuclear Cells. Intervirology 2019; 61:237-246. [PMID: 30889573 DOI: 10.1159/000495179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2017] [Accepted: 10/15/2018] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVE Porcine endogenous retroviruses (PERV) involved in pig to human xenotransplantation have raised great concerns because of their ubiquitous nature in pigs and their ability of infecting human cells in vitro. Although no significant cytopathic effect attributed to PERV was evident on PERV-infected human embryonic kidney 293 (HEK293) cells, we did proteomic analysis to investigate the differences of protein profile in order to further characterize the effect of PERV infection. METHODS HEK293 cells were cocultured with porcine peripheral blood mononuclear cells (PBMCs). Protein profiles of PERV-infected and -noninfected HEK293 cells were analyzed by two-dimensional gel electrophoresis (2-DE). Protein spots with at least 1.5-fold alteration were identified by high-definition mass spectrometry (HDMS) analysis. Then real-time RT-PCR and Western blotting were performed to validate the proteomic results. RESULTS Differential analysis of PERV-infected and -noninfected HEK293 cells by 2-DE revealed ten differentially regulated proteins. The proteins identified by HDMS were involved in various cellular pathways including signal transduction, cell apoptosis, and protein synthesis. CONCLUSION The results of this study revealed differentially expressed proteins in HEK293 cells cocultured with porcine PBMCs and implied that these changes were probably induced by PERV infection. These results provide clues and potential links to understanding the molecular effect of the infection by human-tropic PERV.
Collapse
Affiliation(s)
- Yuyuan Ma
- Beijing Key Laboratory of Blood Safety and Supply Technologies, Institute of Health Service and Transfusion Medicine, Academy of Military Medical Sciences, Beijing, China,
| | - Xiong Zhao
- Beijing Key Laboratory of Blood Safety and Supply Technologies, Institute of Health Service and Transfusion Medicine, Academy of Military Medical Sciences, Beijing, China
| | - Junting Jia
- Beijing Key Laboratory of Blood Safety and Supply Technologies, Institute of Health Service and Transfusion Medicine, Academy of Military Medical Sciences, Beijing, China.,Department of Blood Transfusion, Chinese PLA General Hospital, Beijing, China
| | - Yongxian Yang
- Beijing Key Laboratory of Blood Safety and Supply Technologies, Institute of Health Service and Transfusion Medicine, Academy of Military Medical Sciences, Beijing, China
| | - Rui Fan
- Beijing Key Laboratory of Blood Safety and Supply Technologies, Institute of Health Service and Transfusion Medicine, Academy of Military Medical Sciences, Beijing, China
| | - Maomin Lv
- Beijing Key Laboratory of Blood Safety and Supply Technologies, Institute of Health Service and Transfusion Medicine, Academy of Military Medical Sciences, Beijing, China
| | - Fang Ding
- Beijing Key Laboratory of Blood Safety and Supply Technologies, Institute of Health Service and Transfusion Medicine, Academy of Military Medical Sciences, Beijing, China
| | - Jianmin Wu
- Beijing Key Laboratory of Blood Safety and Supply Technologies, Institute of Health Service and Transfusion Medicine, Academy of Military Medical Sciences, Beijing, China.,Guangxi Veterinary Research Institute, Nanning, China
| | - Jingang Zhang
- Beijing Key Laboratory of Blood Safety and Supply Technologies, Institute of Health Service and Transfusion Medicine, Academy of Military Medical Sciences, Beijing, China
| |
Collapse
|
6
|
Ding XR, Yang J, Lu DD, Li QJ, Zhang ZY, Zhou Z, Wang SQ. Delivery System Targeting Hemagglutinin of Influenza Virus A to Facilitate Antisense-Based Anti-H1N1 Therapy. Bioconjug Chem 2017; 28:1842-1849. [PMID: 28635259 DOI: 10.1021/acs.bioconjchem.7b00124] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Antisense oligonucleotides (ODNs) are therapeutic molecules that hybridize to complementary target mRNA sequences. To further overcome the poor cellular uptake of ODNs, we proposed a novel strategy to deliver ODNs by conjugating the anti-influenza A virus (IAV) ODN with a peptide showing high affinity to the hemagglutinin (HA) on the surface of IAV particles or the IAV-infected host cells. The HA-specific binding peptides were selected by phage display, and the individual binding clones are characterized by DNA sequencing, and the selected phage was further assayed by enzyme-linked immunosorbent assay. The final selected HA-binding peptide, SHGRITFAYFAN, was conjugated to an anti-IAV ODN. The delivery efficiency and the anti-IAV effects of the conjugated molecule were evaluated in a cell-culture and a mouse-infection model. The conjugated molecule was successfully delivered into IAV-infected host cells more efficiently than the anti-IAV ODN in vitro and in vivo. Furthermore, the conjugated molecule protected 80% of the mice from lethal challenge and inhibited the plaque count by 75% compared to the unconjugated molecule (60% and 40%). These findings demonstrate that the delivery of antisense oligodeoxynucleotides to infected tissues by a virus-binding peptide-mediated system is a potential therapeutic strategy against IAV.
Collapse
Affiliation(s)
- Xiao Ran Ding
- Laboratory of Biotechnology, Beijing Institute of Radiation Medicine , Beijing 100850, PR China
| | - Jing Yang
- Laboratory of Biotechnology, Beijing Institute of Radiation Medicine , Beijing 100850, PR China
| | - Dan Dan Lu
- Laboratory of Biotechnology, Beijing Institute of Radiation Medicine , Beijing 100850, PR China
| | - Qing Jun Li
- Laboratory of Biotechnology, Beijing Institute of Radiation Medicine , Beijing 100850, PR China
| | - Zhao Yan Zhang
- Laboratory of Biotechnology, Beijing Institute of Radiation Medicine , Beijing 100850, PR China
| | - Zhe Zhou
- Laboratory of Biotechnology, Beijing Institute of Radiation Medicine , Beijing 100850, PR China
| | - Sheng Qi Wang
- Laboratory of Biotechnology, Beijing Institute of Radiation Medicine , Beijing 100850, PR China
| |
Collapse
|
7
|
Li G, Xu C, Lin X, Qu L, Xia D, Hongdu B, Xia Y, Wang X, Lou Y, He Q, Ma D, Chen Y. Deletion of Pdcd5 in mice led to the deficiency of placenta development and embryonic lethality. Cell Death Dis 2017; 8:e2811. [PMID: 28542142 PMCID: PMC5520688 DOI: 10.1038/cddis.2017.124] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2016] [Revised: 02/23/2017] [Accepted: 02/23/2017] [Indexed: 12/31/2022]
Abstract
Programmed cell death 5 (PDCD5) is an apoptosis promoter molecule that displays multiple biological activities. However, the function of PDCD5 in vivo has not yet been investigated. Here, we generated a Pdcd5 knockout mouse model to study the physiological role of PDCD5 in vivo. Knockout of the Pdcd5 gene resulted in embryonic lethality at mid-gestation. Histopathological analysis revealed dysplasia in both the LZs and JZs in Pdcd5–/– placentas with defects in spongiotrophoblasts and trophoblast giant cells. Furthermore, Pdcd5–/– embryos had impaired transplacental passage capacity. We also found that Pdcd5–/– embryos exhibited cardiac abnormalities and defective liver development. The growth defect is linked to impaired placental development and may be caused by insufficient oxygen and nutrient transfer across the placenta. These findings were verified in vitro in Pdcd5 knockout mouse embryonic fibroblasts, which showed increased apoptosis and G0/G1 phase cell cycle arrest. Pdcd5 knockout decreased the Vegf and hepatocyte growth factor (Hgf) levels, downregulated the downstream Pik3ca–Akt–Mtor signal pathway and decreased cell survival. Collectively, our studies demonstrated that Pdcd5 knockout in mouse embryos results in placental defects and embryonic lethality.
Collapse
Affiliation(s)
- Ge Li
- Department of Immunology, Peking University School of Basic Medical Science, No. 38 Xueyuan Road, Beijing 100191, China.,Key Laboratory of Medical Immunology, Ministry of Health, Peking University Health Sciences Center, No. 38 Xueyuan Road, Beijing 100191, China.,The Clinical Laboratory, Affiliated Hospital of Inner Mongolia Medical University, No. 1 Tongdao North Street, Hohhot, Inner Mongolia 010050, China.,Center for Human Disease Genomics, Peking University, No. 38 Xueyuan Road, Beijing 100191, China
| | - Chentong Xu
- Department of Immunology, Peking University School of Basic Medical Science, No. 38 Xueyuan Road, Beijing 100191, China.,Key Laboratory of Medical Immunology, Ministry of Health, Peking University Health Sciences Center, No. 38 Xueyuan Road, Beijing 100191, China.,Center for Human Disease Genomics, Peking University, No. 38 Xueyuan Road, Beijing 100191, China
| | - Xin Lin
- Department of Immunology, Peking University School of Basic Medical Science, No. 38 Xueyuan Road, Beijing 100191, China.,Key Laboratory of Medical Immunology, Ministry of Health, Peking University Health Sciences Center, No. 38 Xueyuan Road, Beijing 100191, China.,Center for Human Disease Genomics, Peking University, No. 38 Xueyuan Road, Beijing 100191, China
| | - Liujing Qu
- Department of Immunology, Peking University School of Basic Medical Science, No. 38 Xueyuan Road, Beijing 100191, China.,Key Laboratory of Medical Immunology, Ministry of Health, Peking University Health Sciences Center, No. 38 Xueyuan Road, Beijing 100191, China.,Center for Human Disease Genomics, Peking University, No. 38 Xueyuan Road, Beijing 100191, China
| | - Dan Xia
- Department of Immunology, Peking University School of Basic Medical Science, No. 38 Xueyuan Road, Beijing 100191, China.,Key Laboratory of Medical Immunology, Ministry of Health, Peking University Health Sciences Center, No. 38 Xueyuan Road, Beijing 100191, China.,Center for Human Disease Genomics, Peking University, No. 38 Xueyuan Road, Beijing 100191, China
| | - Beiqi Hongdu
- Department of Immunology, Peking University School of Basic Medical Science, No. 38 Xueyuan Road, Beijing 100191, China.,Key Laboratory of Medical Immunology, Ministry of Health, Peking University Health Sciences Center, No. 38 Xueyuan Road, Beijing 100191, China.,Center for Human Disease Genomics, Peking University, No. 38 Xueyuan Road, Beijing 100191, China
| | - Yan Xia
- Department of Immunology, Peking University School of Basic Medical Science, No. 38 Xueyuan Road, Beijing 100191, China.,Key Laboratory of Medical Immunology, Ministry of Health, Peking University Health Sciences Center, No. 38 Xueyuan Road, Beijing 100191, China.,Center for Human Disease Genomics, Peking University, No. 38 Xueyuan Road, Beijing 100191, China
| | - Xiaokun Wang
- Center for Human Disease Genomics, Peking University, No. 38 Xueyuan Road, Beijing 100191, China
| | - Yaxin Lou
- Medical and Healthy Analytical Center, Peking University, No. 38 Xueyuan Road, Beijing 100191, China
| | - Qihua He
- Medical and Healthy Analytical Center, Peking University, No. 38 Xueyuan Road, Beijing 100191, China
| | - Dalong Ma
- Department of Immunology, Peking University School of Basic Medical Science, No. 38 Xueyuan Road, Beijing 100191, China.,Key Laboratory of Medical Immunology, Ministry of Health, Peking University Health Sciences Center, No. 38 Xueyuan Road, Beijing 100191, China.,Center for Human Disease Genomics, Peking University, No. 38 Xueyuan Road, Beijing 100191, China
| | - Yingyu Chen
- Department of Immunology, Peking University School of Basic Medical Science, No. 38 Xueyuan Road, Beijing 100191, China.,Key Laboratory of Medical Immunology, Ministry of Health, Peking University Health Sciences Center, No. 38 Xueyuan Road, Beijing 100191, China.,Center for Human Disease Genomics, Peking University, No. 38 Xueyuan Road, Beijing 100191, China
| |
Collapse
|
8
|
Wang W, Song XW, Zhao CH. Roles of programmed cell death protein 5 in inflammation and cancer (Review). Int J Oncol 2016; 49:1801-1806. [PMID: 27826615 DOI: 10.3892/ijo.2016.3706] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2016] [Accepted: 09/19/2016] [Indexed: 11/06/2022] Open
Abstract
PDCD5 (programmed cell death 5) is an apoptosis related gene cloned in 1999 from a human leukemic cell line. PDCD5 protein containing 125 amino acid (aa) residues sharing significant homology to the corresponding proteins of species. Decreased expression of PDCD5 has been found in many human tumors, including breast, gastric cancer, astrocytic glioma, chronic myelogenous leukemia and hepatocellular carcinoma. In recent years, increased number of studies have shown the functions and mechanisms of PDCD5 protein in cancer cells, such as paraptosis, cell cycle and immunoregulation. In the present review, we provide a comprehensive review on the role of PDCD5 in cancer tissues and cells. This review summarizes the recent studies of the roles of PDCD5 in inflammation and cancer. We mainly focus on discoveries related to molecular mechanisms of PDCD5 protein. We also discuss some discrepancies between the current studies. Overall, the current available data will open new perspectives for a better understanding of PDCD5 in cancer.
Collapse
Affiliation(s)
- Wei Wang
- Department of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang, Liaoning 110122, P.R. China
| | - Xiao-Wen Song
- Department of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang, Liaoning 110122, P.R. China
| | - Cheng-Hai Zhao
- Department of Pathophysiology, College of Basic Medical Science, China Medical University, Shenyang, Liaoning 110122, P.R. China
| |
Collapse
|
9
|
Li G, Ma D, Chen Y. Cellular functions of programmed cell death 5. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH 2016; 1863:572-80. [PMID: 26775586 DOI: 10.1016/j.bbamcr.2015.12.021] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/26/2015] [Revised: 12/24/2015] [Accepted: 12/29/2015] [Indexed: 01/01/2023]
Abstract
Programmed cell death 5 (PDCD5) was originally identified as an apoptosis-accelerating protein that is widely expressed and has been well conserved during the process of evolution. PDCD5 has complex biological functions, including programmed cell death and immune regulation. It can accelerate apoptosis in different type of cells in response to different stimuli. During this process, PDCD5 rapidly translocates from the cytoplasm to the nucleus. PDCD5 regulates the activities of TIP60, HDAC3, MDM2 and TP53 transcription factors. These proteins form part of a signaling network that is disrupted in most, if not all, cancer cells. Recent evidence suggests that PDCD5 participates in immune regulation by promoting regulatory T cell function via the PDCD5-TIP60-FOXP3 pathway. The stability and expression of PDCD5 are finely regulated by other molecules, such as NF-κB p65, OTUD5, YAF2 and DNAJB1. PDCD5 is phosphorylated by CK2 at Ser119, which is required for nuclear translocation in response to genotoxic stress. In this review, we describe what is known about PDCD5 and its cellular functions.
Collapse
Affiliation(s)
- Ge Li
- Department of Immunology, Peking University School of Basic Medical Sciences, 38 Xueyuan Road, Beijing 100191, China; Center for Human Disease Genomics, Peking University, 38 Xueyuan Road, Beijing 100191, China
| | - Dalong Ma
- Department of Immunology, Peking University School of Basic Medical Sciences, 38 Xueyuan Road, Beijing 100191, China; Center for Human Disease Genomics, Peking University, 38 Xueyuan Road, Beijing 100191, China
| | - Yingyu Chen
- Department of Immunology, Peking University School of Basic Medical Sciences, 38 Xueyuan Road, Beijing 100191, China; Center for Human Disease Genomics, Peking University, 38 Xueyuan Road, Beijing 100191, China.
| |
Collapse
|
10
|
Zhang S, Li G, Fu X, Qi Y, Li M, Lu G, Hu J, Wang N, Chen Y, Bai Y, Cui M. PDCD5 protects against cardiac remodeling by regulating autophagy and apoptosis. Biochem Biophys Res Commun 2015; 461:321-8. [PMID: 25881505 DOI: 10.1016/j.bbrc.2015.04.032] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2015] [Accepted: 04/05/2015] [Indexed: 01/06/2023]
Abstract
Cardiac remodeling, including cardiac hypertrophy and fibrosis, is an important pathological process that can lead to heart failure. A previous study demonstrated that autophagy could represent an active adaptive response in cardiomyocytes that affords protection from cardiac remodeling. In the present study, we investigated the role of an autophagy-related gene, PDCD5 (Programmed cell death 5), in cardiac remodeling induced by β-adrenergic stimulation in vivo. We report for the first time that mice systemically overexpressing PDCD5 (PDCD5tg) were protected from cardiac remodeling. In addition, cardiac function was preserved in PDCD5tg mice in response to isoproterenol (ISO) stimulation. Importantly, basal autophagy was significantly higher in PDCD5tg mice than in the wild-type (WT) mice. Moreover, apoptosis was significantly lower in PDCD5tg mice than in WT mice, among the ISO-induced animals. In summary, our findings reveal that PDCD5 overexpression improves cardiac function and inhibits cardiac remodeling induced by ISO via induction of autophagy and inhibition of apoptosis.
Collapse
Affiliation(s)
- Shu Zhang
- Department of Cardiology, Peking University Third Hospital and Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education and Beijing Key Laboratory of Cardiovasicular Receptors Research, Beijing 100191, China
| | - Ge Li
- Key Laboratory of Medical Immunology, Ministry of Health, Peking University Health Science Center, Beijing 100191, China
| | - Xin Fu
- Department of Cardiology, Peking University Third Hospital and Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education and Beijing Key Laboratory of Cardiovasicular Receptors Research, Beijing 100191, China
| | - Yanchao Qi
- Department of Cardiology, Peking University Third Hospital and Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education and Beijing Key Laboratory of Cardiovasicular Receptors Research, Beijing 100191, China
| | - Mengtao Li
- Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Guang Lu
- Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Jia Hu
- Key Laboratory of Medical Immunology, Ministry of Health, Peking University Health Science Center, Beijing 100191, China
| | - Nan Wang
- Department of Cardiology, Peking University Third Hospital and Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education and Beijing Key Laboratory of Cardiovasicular Receptors Research, Beijing 100191, China
| | - Yingyu Chen
- Key Laboratory of Medical Immunology, Ministry of Health, Peking University Health Science Center, Beijing 100191, China
| | - Yun Bai
- Department of Cell Biology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
| | - Ming Cui
- Department of Cardiology, Peking University Third Hospital and Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health, Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education and Beijing Key Laboratory of Cardiovasicular Receptors Research, Beijing 100191, China.
| |
Collapse
|